Skip to content

Koo, one of the leading researchers of Psoriasis

San Francisco Salt Company Teams Up With the National Psoriasis Foundation for 2015 Events. States to honor Dr. Koo, one of the leading researchers of Psoriasis. This event will draw in all the major supporters from around the United States to honor Dr. Koo, one of the leading researchers of Psoriasis. John Koo, M.D. Ethan Levin, M.D. Investigator, Oregon Medical Research Center, Portland, Ore. Erin Boh, M.

Koo, one of the leading researchers of Psoriasis 2Koo and his colleagues published a paper in the Journal of the American Academy of Dermatology last month that showed people with untreated psoriasis experience similar emotional distress to people with other major medical diseases such as congestive heart failure, breast cancer and diabetes. Many people who have skin psoriasis go on to develop a form of arthritis called psoriatic arthritis, and the inflammatory disease has been associated with inflammation in the vessels of the brain and heart, leading to an increased risk of heart attack and stroke. Koo’s research also focuses on the psychological aspects of the disease, due in part to his background as a psychiatrist. One is to try to make them feel better, and the second way is to get rid of the psoriasis. Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin. It typically presents with red patches with white scales on top. Around one-third of people with psoriasis report a family history of the disease, and researchers have identified genetic loci associated with the condition. Researchers have proposed differing descriptions of psoriasis and psoriatic arthritis; Beroukhim K, Danesh MJ, Nguyen C, Austin A, Koo J, Levin E. Anti-IL-23 Phase II Data for Psoriasis: A Review. J Drugs Dermatol. 2015 Oct 1; 14(10):1093-6.

Researchers have discovered that a variation in a group of genes known as LCE can protect against the condition. The skin cannot shed these cells quickly enough, so they build up, leading to thick, dry patches, or plaques. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Age-and sex-adjusted Cox models were created for each of the leading causes of death defined by the Centers for Disease Control. Psoriasis is a chronic inflammatory disease affecting 13 of the population. We performed a cohort study to determine the risk of the most common forms of death in patients with severe psoriasis, using the General Practice Research Database (GPRD) from the United Kingdom. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Because adherence to topical treatment can be a major hurdle, keeping the treatment regimen simple and using treatment vehicles that the patient finds acceptable is often beneficial. However, in clinical practice, complicating the treatment regimen with more than one topical product A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes.


Koo, one of the leading researchers of Psoriasis 3However, researchers are still unsure as to exactly how the disease is inherited. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Psoriasis continues to be one of the more difficult skin conditions to treat. There is no cure for psoriasis but several new medications have recently been introduced and ongoing research looks promising. Methotrexate tablets are taken once a week and can lead to dramatic improvement over two to three months. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R; American Academy of Dermatology. This is one of the largest grants ever given to a medical institution in the United States for the study of psoriasis. A Center of Research Translation (CORT) in Psoriasis based at University Hospitals Case Medical Center will integrate a strong psoriasis and skin disease research base with a large existing cohort of psoriasis patients. To receive a certificate, you must receive a passing score as designated at the top of the test. No one knows for certain exactly what causes psoriasis and, as mentioned, there is no cure, although the latest studies strongly suggest it may be related to an immune system problem that triggers inflammation the body cannot control on its own. Recent studies are leading researchers to believe that the misbehaving cytokines can also increase insulin resistance in the liver and muscles, and destroy insulin-producing cells in the pancreas, ultimately leading to the development of diabetes. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al.


Dr. John Koo is the director of the Psoriasis, Phototherapy and Skin Treatment Clinic. His main interest is in psoriasis therapy, phototherapy, eczema psychodermatology and quality of life research. One in three people with psoriasis do not receive proper treatment due to health insurance issues: Survey. PhotoMedex, Inc. announced today that John Koo, MD will be the principal investigator in a clinical study assessing the efficacy of the XTRAC Velocity excimer laser in the treatment of generalized psoriasis when used in combination with Clobex spray. Dr. Koo is world-renowned for his research and advocacy in fighting this disease. This is not top level care I expected seeing his acclaimed reputation. Dr. Koo solved by eczema in one appointment after I’d seen several derms. His office runs super smoothly. Researchers have discovered that a variation in a group of genes known as LCE can protect against the condition. Combination therapies are often more effective than one treatment alone. The main disease activity leading to psoriasis occurs in the epidermis, the top five layers of the skin. Asztalos ML, Heller MM, Lee ES, Koo J. The impact of emollients on phototherapy: a review.

The UCSF Psoriasis and Skin Treatment Center has one opening for a full-time, clinical research fellow effective. The fellow will also have the unique opportunity to work in our psycho-dermatology clinic with Dr. John Koo, the only physician in the country boarded in both dermatology and psychiatry. Table 1: Drugs involved in the treatment of psoriasis. Research continues to elucidate new pathological mechanisms and develop new oral agents including Janus kinase (Jak), protein kinase C (PKC), and mitogen-activated protein kinase (MAPK) inhibitors (Figure 2). This antagonist blocks the activation of TLRs7, TLRs9, and MyD88 proteins, which normally activate signal transduction pathways leading to the production of inflammatory cytokines. Psoriasis is one of the prevalent skin conditions in the United States. Moreover, PASI is the most widely used measure of severity in the research as well as the clinical setting. The Koo-Menter Psoriasis Instrument (KMPI) is a diagnostic algorithm and a formal measure, to aid in identifying patients with significant impact on QoL warranting systemic therapy. Physicians should also ask a few leading questions about how psoriasis influences the patient’s life. Does smoking and drinking affect psoriasis? Recent studies have shown that not only can alcohol and cigarettes worsen psoriasis symptoms, but a number of researchers believe that they may actually cause psoriasis in some patients. In 2005, SKINMed magazine printed an article by Behnam, Behnam, and Koo that corroborated many of Naldi’s findings, as well pointing out that, in addition to a greater risk of developing psoriasis, those already suffering, especially men, were more likely to experience more severe symptoms, especially in their extremities. One notable reason is that patients often consume both alcohol and tobacco together, and therefore it is difficult to control for the effects of one or the other and thus to definitively attribute the symptoms to one or the other.